Table 1.
Demographic, Hematologic, and Engraftment Features of Patients Enrolled Onto the NKAML Study
| UPN | At Diagnosis |
Recipient |
Donor KIR Mismatch* | Donor Ligand Mismatch† | Peak NK Cell Chimerism |
NK Cell Graft |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | Sex | WBC (109/L) | Karyotype | FAB | HLA-Bw | HLA-C | Day | % Donor | NK Cells (106/kg) | T Cells (106/kg) | B Cells (106/kg) | |||
| 1 | 0.9 | F | 20 | 46,XX | M5 | 4/6 | Asn80/Lys80 | None | None | 7 | 7 | 38.7 | ND | 0.106 |
| 2 | 3 | F | 14 | t(1;22) | M7 | 6/6 | Asn80/Asn80 | 2DL1, 3DL1 | None | 7 | 2 | 27.2 | ND | 1.700 |
| 3 | 0.2 | F | 41 | t(1;22) | M7 | 4/6 | Asn80/Asn80 | 2DL1 | Lys80 | 28 | 30 | 31.1 | ND | 0.652 |
| 4 | 2 | M | 145 | inv(16) | M4Eo | 4/4 | Asn80/Asn80 | 2DL1 | None | 2 | 6 | 37.3 | ND | 0.148 |
| 5 | 0.7 | M | 488 | t(9;11) | M5 | 6/6 | Lys80/Lys80 | 2DL2/3, 3DL1 | Bw4, Asn80 | 7 | 3 | 80.9 | ND | 0.135 |
| 6 | 11 | F | 32 | t(16;16) | M4Eo | 6/6 | Asn80/Asn80 | 2DL1, 3DL1 | Bw4 | 14 | 8 | 5.2 | ND | 0.007 |
| 7 | 21 | M | 110 | +21 | M1 | 4/6 | Asn80/Asn80 | 2DL1 | None | 7 | 1 | 7.3 | ND | 0.004 |
| 8 | 17 | F | 137 | t(16;16) | M4Eo | 4/4 | Lys80/Lys80 | 2DL2/3 | Asn80 | 28 | 29 | 13.3 | 0.001 | ND |
| 9 | 8 | M | 84 | t(16;16) | M4Eo | 6/6 | Asn80/Lys80 | 3DL1 | None | 7 | 15 | 47.7 | ND | 0.087 |
| 10 | 2 | M | 4 | t(11;19) | M5 | 6/6 | Asn80/Asn80 | 2DL1, 3DL1 | Lys80 | 7 | 2 | 13.4 | ND | 0.082 |
Abbreviations: NKAML, Pilot Study of Haploidentical Natural Killer Cell Transplantation for Acute Myeloid Leukemia; UPN, unique patient number; FAB, French-American-British; HLA, human leukocyte antigen; KIR, killer immunoglobulin-like receptor; NK, natural killer; ND, not determinable (ie, less than the detection threshold of 0.001).
*
Receptor-ligand model.
†
Ligand-ligand model.